Background: Anti-dementia drugs may improve gait performance. No comparison between acetylcholinesterase inhibitors (CEIs) and memantine-related changes in gait variability has been reported. The objectives of this study were to 1) quantify and compare the mean values and coefficients of variation (CoV) of stride time in demented patients with Alzheimer’s disease and related disorders (ADRD) before […]
Background: Only half of those living with Alzheimer’s disease in France are currently diagnosed, and only one patient in three is supported during the early stages of dementia. This study aims to evaluate three cognitive tests for their predictive ability to diagnose mild cognitive impairments and Alzheimer’s disease and related disorders. For people aged 65 […]
Background: Current treatments for Alzheimer’s disease and related disorders (ADRD) are symptomatic and can only temporarily slow down ADRD. Future possibilities of care rely on multi-target drugs therapies that address simultaneously several pathophysiological processes leading to neurodegeneration. We hypothesized that the combination of memantine with vitamin D could be neuroprotective in ADRD, thereby limiting neuronal […]
Background: No comparison of anti-dementia drugs-related gait changes has been previously conducted combining single and dual task assessments.; Objectives: (1) To quantify and compare gait changes among patients with possible or probable Alzheimer’s disease before and after the use of acetylcholinesterase inhibitors (i.e., donepezil, galantamine, rivastigmine) or memantine, and among controls with possible or probable […]